665 related articles for article (PubMed ID: 24461315)
21. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial.
Malaguarnera M; Gargante MP; Russo C; Antic T; Vacante M; Malaguarnera M; Avitabile T; Li Volti G; Galvano F
Am J Gastroenterol; 2010 Jun; 105(6):1338-45. PubMed ID: 20068559
[TBL] [Abstract][Full Text] [Related]
22. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
[TBL] [Abstract][Full Text] [Related]
23. Oral coenzyme Q10 supplementation in patients with nonalcoholic fatty liver disease: effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress.
Farhangi MA; Alipour B; Jafarvand E; Khoshbaten M
Arch Med Res; 2014 Oct; 45(7):589-95. PubMed ID: 25450583
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
25. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
26. Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial.
Darvish Damavandi R; Shidfar F; Najafi M; Janani L; Masoodi M; Akbari-Fakhrabadi M; Dehnad A
Phytother Res; 2021 Jun; 35(6):3145-3156. PubMed ID: 33880813
[TBL] [Abstract][Full Text] [Related]
27. Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients.
Jin HB; Gu ZY; Yu CH; Li YM
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):389-92. PubMed ID: 16109522
[TBL] [Abstract][Full Text] [Related]
28. Insulin resistance and metabolic syndrome in patients with NAFLD but without diabetes: effect of a 6 month regime intervention.
Cankurtaran M; Tayfur O; Yavuz BB; Geyik S; Akhan O; Arslan S
Acta Gastroenterol Belg; 2007; 70(3):253-9. PubMed ID: 18074733
[TBL] [Abstract][Full Text] [Related]
29. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Samy W; Hassanian MA
Arab J Gastroenterol; 2011 Jun; 12(2):80-5. PubMed ID: 21684478
[TBL] [Abstract][Full Text] [Related]
30. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
[TBL] [Abstract][Full Text] [Related]
31. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Chen S; Zhao X; Ran L; Wan J; Wang X; Qin Y; Shu F; Gao Y; Yuan L; Zhang Q; Mi M
Dig Liver Dis; 2015 Mar; 47(3):226-32. PubMed ID: 25577300
[TBL] [Abstract][Full Text] [Related]
32. Association of hepatic insulin resistance indexes to nonalcoholic fatty liver disease and related biomarkers.
Sesti G; Fiorentino TV; Hribal ML; Sciacqua A; Perticone F
Nutr Metab Cardiovasc Dis; 2013 Dec; 23(12):1182-7. PubMed ID: 23419734
[TBL] [Abstract][Full Text] [Related]
33. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
Nobili V; Manco M; Ciampalini P; Alisi A; Devito R; Bugianesi E; Marcellini M; Marchesini G
Clin Ther; 2008 Jun; 30(6):1168-76. PubMed ID: 18640473
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
[TBL] [Abstract][Full Text] [Related]
35. The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease.
Sheng X; Che H; Ji Q; Yang F; Lv J; Wang Y; Xian H; Wang L
Horm Metab Res; 2018 May; 50(5):397-402. PubMed ID: 29723898
[TBL] [Abstract][Full Text] [Related]
36. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients.
Verrijken A; Francque S; Mertens I; Talloen M; Peiffer F; Van Gaal L
Int J Obes (Lond); 2010 May; 34(5):899-907. PubMed ID: 20142825
[TBL] [Abstract][Full Text] [Related]
37. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
38. The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes.
Aso Y; Terasawa T; Kato K; Jojima T; Suzuki K; Iijima T; Kawagoe Y; Mikami S; Kubota Y; Inukai T; Kasai K
Transl Res; 2013 Nov; 162(5):309-16. PubMed ID: 23994650
[TBL] [Abstract][Full Text] [Related]
39. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH
Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638
[TBL] [Abstract][Full Text] [Related]
40. Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease.
Hong X; Tang H; Wu L; Li L
J Pharm Pharmacol; 2006 Oct; 58(10):1391-8. PubMed ID: 17034663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
